On-demand CVT-301 meets for PD motor fluctuations

Civitas Therapeutics Inc. (Chelsea, Mass.) said on-demand treatment with inhaled CVT-301 met the primary endpoint vs. placebo in the Phase IIb CVT-301-003 trial to treat motor fluctuations associated with Parkinson's disease (PD). CVT-301 reduced mean Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores at week four vs. placebo (p<0.001). The double-blind, international trial enrolled 86 PD patients experiencing motor fluctuations, or "off" phenomena. Data are slated to be presented on Tuesday at the American Academy of Neurology meeting. ...